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nterpreting the Music
f Drug-Eluting Stents
alcyon Song or Albatross Dirge?*
aniel B. Mark, MD, MPH, FACC
urham, North Carolina
hen drug-eluting stents (DES) were introduced clinically
n 2003 as the long-sought cure for restenosis, the Center
or Medicare and Medicaid Services (CMS) was so per-
uaded that these devices were a breakthrough technology
hat it took the almost unprecedented step of increasing
eimbursement to account for their substantially greater
ost. Debating the appropriate use of this technology,
nterventional cardiologists in the U.S. worried that they
ight be judged guilty of medical malpractice if they failed
o provide DES wherever possible in patients undergoing
ercutaneous intervention (PCI). Within a few years, DES
ere being routinely used in over 80% of all PCIs across the
.S. and in several European countries.
See page 1844
For a brief halcyon period, it seemed that if cost were no
bject, all PCI patients should be given a drug-eluting
ather than a bare-metal stent (BMS) wherever technically
easible. Then, in September 2006 at the World Congress of
ardiology meeting in Barcelona, the winds began to shift.
everal groups presented data suggesting that DES were
ssociated with a small post–1-year excess risk of stent
hrombosis relative to BMS. Particularly concerning was the
uggestion that relative to other types of acute coronary
yndromes, DES thrombosis events seemed to be associated
ith exceptionally high rates of mortality and morbidity.
he press sounded the alarm, concerned patients called
heir doctors asking whether they should have their stents
emoved, and the Food and Drug Administration convened
panel of experts to review the matter (1). Over 2 days in
ecember 2006, this panel reviewed evidence from a wide
ariety of sources and heard the views of many experts. In
he end, the panel reached the not-surprising conclusions
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Duke University Medical Center, Duke Clinical Research Institute,t
urham, North Carolina. Dr. Mark has received $10,000 in grant funding and
$10,000 in consulting fees from Medtronic.hat there was some reason for concern but that the evidence
as far from clear and (of course) more evidence was needed
2). Cardiologists, who in the meantime were faced with the
ragmatic problem of caring for patients with coronary
rtery disease, were left wondering how to navigate the
hoppy waters in which they now found themselves.
In this issue of the Journal, Garg et al. (3) present a
ecision-model–based quantitative analysis to help clarify
he health outcome trade-offs between BMS with higher
isk of target vessel repeat revascularization and DES with
ossible increased risk of very late stent thrombosis. Of the
lements required for this modeling exercise on the BMS
ide, the least certain is the negative health outcome weight
hat should be assigned to repeat revascularization proce-
ures performed for restenosis after stenting. To compare 2
reatment strategies in terms of net expected quality-
djusted life years (QALYs), the impact of restenosis must
e expressed in terms either of life expectancy or quality of
ife lost. The standard utility theory approach requires
etermining how much of remaining life expectancy pa-
ients would be willing to forgo to avoid restenosis with
epeat revascularization. For this parameter, Garg et al. (3)
eferred to previous work in the Stent-PAMI (Stent-
rimary Angioplasty in Myocardial Infarction) trial where
hey found that patients without repeat revascularization
ad a 0.06 absolute advantage in quality adjusted life
xpectancy over patients with repeat revascularization (4).
sing these data in the current model, Garg et al. (3) are in
ssence assuming that patients would be willing to trade 22
ays of life in excellent health to avoid a repeat revascular-
zation procedure. Although this estimate might be reason-
ble, it is important to recognize that it does not reflect the
udgments of patients directly grappling with this difficult
uestion.
The most critical and elusive aspect of this decision
roblem is the true risk of very late stent thrombosis with
urrent generation DES (5). Detecting a presumed tiny
bsolute difference of 0.1% to 0.5% annually with precision
ould require over 10,000 patients followed for 3 or more
ears. Detecting this difference with shorter follow-up
ould raise the sample size requirements. Compounding
hese signal detection difficulties are problems in determin-
ng whether a late cardiac event in a coronary artery disease
atient with prior PCI is due to stent thrombosis. If the
atient dies before invasive study and no postmortem
xamination is performed or is not referred for invasive
tudy, there is no way to be certain that the DES was
nvolved in the acute ischemic event.
For these and other reasons, we cannot now determine
hether there is a small but important excess risk of very
ate stent thrombosis with DES. To assess how this
ossibility can and should affect our decisions, we must
se modeling as Garg et al. (3) have done. They begin by
onsidering the choice between DES and BMS assuming
hat there is no late excess risk of stent thrombosis. In
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May 13, 2008:1854–6 Editorial Commenthis situation, DES improves clinical outcomes through
ewer repeat revascularization procedures, thereby pro-
iding a modest improvement in quality-adjusted survival
ver BMS. Disregarding cost, if lowering the probability
f repeat revascularization is of some value to the well
eing of patients, the decision to routinely use DES is not
ontroversial.
In the second pivotal case considered by Garg et al. (3),
ES are assumed to have an excess risk of stent thrombosis
fter the first year of 0.13%/year for at least the next 3 years.
n that scenario, the QALY benefits of the DES noted in
he preceding text are cancelled out by the morbidity and
ortality of these late adverse events so that the net difference
n favor of the DES is 0.001 QALYs or approximately 9
xtra hours of life in excellent health. If the excess risk of
tent thrombosis is increased over 0.14% from 0.13%/year,
he BMS strategy now provides the higher net yield of
ALYs and becomes the preferred treatment.
Two important parameters were identified in sensitiv-
ty analysis as key determinants of the outcome of this
odel: the risks of restenosis with BMS and the length of
ime over which DES might continue to have an excess
isk of stent thrombosis. According to this model, one
hould be willing to accept higher levels of risk of very
ate stent thrombosis for patients with higher risks of
estenosis. Conversely, the longer we believe the elevated
isk of very late stent thrombosis persists, the more we
hould favor the use of BMS. Importantly, the authors do
ot consider the possibility that extended use of clopi-
ogrel, in addition to aspirin, beyond the first year after
CI might protect against this excess stent thrombosis
isk at the cost of extra major bleeds (leaving aside the
onetary cost of the therapy) (6).
The primary conclusion of this analysis can be restated
s follows: the choice between a DES with a slight excess
isk of stent thrombosis after the first year and a BMS
ith a much higher probability of restenosis requiring
epeat revascularization during the first year is a toss-up
i.e., a situation in which the consequences of the 2
hoices are so close as to be indistinguishable) (7).
owever, 1 further characteristic of a toss-up is that the
ajor clinical outcomes are of equivalent value. Whether
his condition is met in the present analysis depends on
hether one accepts the trade of extra nonfatal revascular-
zations for a much smaller risk of DES thrombosis that
ould result in disability or death. The decision model by
arg et al. (3) assumes that patients are risk neutral with
egard to this trade. In other words, they will choose the
utcome with the higher net QALYs value regardless of
ow those QALYs are produced. Because very late stent
hrombosis events have not translated into consistent eleva-
ions in overall mortality in DES patients relative to BMS
atients, some interventionalists seem quite comfortable
ith this trade (5,8). As noted previously, however, studies
eported to date have insufficient statistical power to deal
ith such small event rates. In such cases, the absence tf evidence should not be confused with evidence of
bsence (9).
Although interventionalists might accept a trade between
estenosis and very late stent thrombosis, patients are not so
learly risk neutral. They might be willing to accept some
isk to avoid serious adverse health events such as death or
isabling stroke, but things are less clear regarding the
illingness to accept risk to avoid transient turbulence in
heir health that does not result in death or long-term
isability. Indeed, Garg et al. (3) showed in sensitivity
nalysis that patients who are not willing to trade some of
heir remaining life expectancy to avoid repeat revascular-
zation would have a much lower willingness to accept the
ate risks of DES.
Obviously, we need more data about the magnitude of
ate adverse events with DES. However, owing to the huge
umber of patients required and the difficulties of case
nding in such studies, we cannot expect that this question
ill be easily or quickly settled. How then should these
nsights inform our clinical practice? Reserving DES for
atients with the highest risk of restenosis is 1 reasonable
trategy that improves the likely margin of benefit in
ALYs for these devices. Since the reports at the World
ongress of Cardiology in 2006, the use of DES has fallen
ignificantly. Whether DES are in fact being selectively
irected at the patients with the highest risk of restenosis
equires empirical verification. Some clinicians have also
hosen to assume that indefinite use of clopidogrel will
rotect against very late stent thrombosis. However, we lack
linical trial validation of this hypothesis as well as data on
he long-term risk/benefit ratio and on the cost-effectiveness
f such therapy (10).
There is also the issue of what patients want. Do they
eel as passionately as interventional cardiologists about
voiding clinical restenosis? Are they really able to
ppreciate incremental risks on the order of magnitude of
to 5 of 1,000? How does the prospect of years of
rophylactic clopidogrel therapy affect their preferences?
iven the tremendous susceptibility of patients’ decisions
o framing bias, can we even provide a fair exposition of
he problem and its attendant uncertainties and expect
hem to process the information and make a treatment
election on that basis? The analysis of Garg et al. (3)
oes reassure us that, for a risk-neutral individual who is
illing to trade a small amount of life expectancy for a
educed risk of repeat target lesion revascularization, the
choices produce almost the same net clinical benefit, so
ither should be satisfactory. However, the issue of very
ong-term clopidogrel therapy in this decision problem
oes require further consideration.
Finally, the next generation drug– device combina-
ions, already in use in Europe and now being introduced
n the U.S., might provide different safety and efficacy
rofiles. Hopefully, the lessons of the last few years will
each us what data we require about these new devices
hat will allow us to shed the albatross of very late stent
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